CYTK · Cytokinetics, Incorporated — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on CYTK. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About CYTK · Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Live Quote
BUY (score +8) · 12-1 mom 133.7% · RSI 65.9 · above_both · 0.0% from high
Targets blend Wall Street consensus (20 analysts: low $69.00 / mean $105.60 / high $146.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the active anti-signals (dilution, going concern, high burn) and lack of fundamental edge justify a skip.
Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the active anti-signals (dilution, going concern, high burn) and lack of fundamental edge justify a skip.
Cytokinetics has a commercial product (MYQORZO/aficamten) newly launched in Q1 2026 following FDA approval Dec 2025 and EU launch June 2026. The stock is near all-time highs at $73.68 (52w high $80.20), up ~152% over 1 year, on strong MYQORZO early commercial traction. Insider Form 4 filings are extremely active in the last 14 days but ALL transactions reviewed were SELLs by directors and employees (exercise of options + immediate sale) — no open-market P/S purchases verified despite the cluster trigger. CEO Blum sold $446K on 04/29, EVP Malik exercised options and sold ~$270K on 05/05, Director Kaye sold $223K on 06/01, Director Parshall sold $370K on 06/01 — all at various price points. This is a high-quality company with real product traction but the stock is fully-valued (no forward PE given pre-profitability; EV/EBITDA N/A) and near its 52w ceiling. The insider cluster reflects compensation-related exercise-and-sell activity, not conviction buying.